A patient with hairy cell leukemia (HCL) may show disease progression after being treated. A patient with evidence for disease progression may require additional or novel therapy.

Criteria for disease progression:

(1) an increase in symptoms related to disease (fatigue, frequent infection, other)

(2) >= 25% decline in hematologic parameters

(3) >= 25% increase in organomegaly (relative to nadir measurements after therapy)


The diagnosis of progression requires exclusion of:

(1) therapy-related myelosuppression

(2) therapy-related immunosuppression

To read more or access our algorithms and calculators, please log in or register.